Lv2
110 积分 2024-09-08 加入
Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients
4天前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
5天前
已完结
Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib
5天前
已完结
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
5天前
已完结
Long-term Survival Case of SCLC Transformation After Osimertinib Resistance in EGFR-mutant NSCLC: Benefits from Chemo-immunotherapy Combined with Anti-angiogenic Therapy Followed by Osimertinib Rechallenge
5天前
已完结
Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A
5天前
已完结
Long-term Survival Case of SCLC Transformation After Osimertinib Resistance in EGFR-mutant NSCLC: Benefits from Chemo-immunotherapy Combined with Anti-angiogenic Therapy Followed by Osimertinib Rechallenge
19天前
已完结
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
28天前
已完结
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure
28天前
已完结
Long-term Survival Case of SCLC Transformation After Osimertinib Resistance in EGFR-mutant NSCLC: Benefits from Chemo-immunotherapy Combined with Anti-angiogenic Therapy Followed by Osimertinib Rechallenge
1个月前
已完结
皖公网安备34019202002308
